Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary...

Keywords

ClopidogrelMedicineAspirinPlateletLoading doseInternal medicinePlatelet aggregation inhibitorPharmacologyCardiologyMyocardial infarctionAnesthesiaAcute coronary syndromeAntagonistTiclopidinePlatelet aggregationReceptor

Affiliated Institutions

Related Publications

Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose

Jean‐Philippe Collet , Johanne Silvain , Antoine Landivier +8 more

Background— Clopidogrel loading has mostly been studied in clopidogrel-naïve patients. Whether clopidogrel-treated patients readmitted for an acute coronary syndrome or percuta...

2008 Circulation 87 citations

Pharmacology of CS-747 (prasugrel, LY640315), a Novel, Potent Antiplatelet Agent with in Vivo P2Y<sub>12</sub>Receptor Antagonist Activity

Y. Niitsu , Joseph A. Jakubowski , Atsuhiro Sugidachi +1 more

CS-747 (prasugrel, LY640315) is a member of the thienopyridine class of oral platelet aggregation inhibitors that includes ticlopidine and clopidogrel. A single oral administrat...

2005 Seminars in Thrombosis and Hemostasis 233 citations

Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes

The PURSUIT trial investigators

Inhibition of platelet aggregation with eptifibatide reduced the incidence of the composite end point of death or nonfatal myocardial infarction in patients with acute coronary ...

1998 New England Journal of Medicine 1435 citations

Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits.

Jean‐Marc Herbert , A Tissinier , G. Defreyn +1 more

The possible activity of ticlopidine and its analogue clopidogrel in early atherogenesis was investigated. Incubation of rabbit platelets with the extracellular matrix produced ...

1993 Arteriosclerosis and Thrombosis A Jou... 104 citations

Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y <sub>12</sub> Antagonist, With Clopidogrel in Percutaneous Coronary Intervention

Stephen D. Wiviott , Elliott M. Antman , Kenneth J. Winters +8 more

Background— Despite the current standard antiplatelet regimen of aspirin and clopidogrel (with or without glycoprotein IIb/IIIa inhibitors) in percutaneous coronary intervention...

2005 Circulation 378 citations

Publication Info

Year: 2007
Type: article
Volume: 50
Issue: 19
Pages: 1852-1856
Citations: 483
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

483

OpenAlex

Cite This

APA Style

                            
                                
                                    Robert F. Storey, 
                                
                                    Steen Husted, 
                                
                                    Robert A. Harrington
                                
                                et al.
                            
                            (2007). 
                            Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes. 
                            Journal of the American College of Cardiology
                            , 50
                            (19)
                            , 1852-1856.
                            https://doi.org/10.1016/j.jacc.2007.07.058
                        

Identifiers

DOI: 10.1016/j.jacc.2007.07.058